Primo muddies the data. sad.
although you could argue that dosages being the same means that conditions are similar.
Cyp versus E at 600 seems about the same, (at least for free T, the stuff that matters) accounting for ester weight. E2 differences are interesting.
Also, back when he talked about this he painted it as a larger study he designed, not a n=1 case study.
Would be nice to see a larger sample.
"Methenolone (Primobolan) was held constant during both phases to mitigate aromatization and support anabolic stability."
Which to me is ridiculous, the best way to mitigate aromatization is to use an aromatase inhibitor, which like the name indicates..
What I don't understand aswell is the 'support anabolic stability' claim.
ChatGPT says it's there to maintain a stable DHT derivative, but Primobolan dase increases aswell with Testosterone
perfectly fine for a scientific case study. it can technically be used ro mitigate E2 conversion. They cant tell the individual (even if it is kurt havens himself) to run a specific compound, due to research ethics. Genuinely cant tell them (subjects) shit in regards to what to take otherwise any ethics committee worth their salt is gonna tell you to remove yourself and never do any research again. They are strict asf with that stuff.
The "support anabolic stability" is just a phrase to acknowledge that it does have anabolic properties, so noone can "um ackchually" them.
Also, the paragraph talking about the elevated E2 is faulty. either that or the ?Spreadsheet? idk how to say it (the table containing the data) is wrong as 12.4 pg/ml E2 is definitely NOT elevated. the only E2 value that could be elevated under VERY strict reference ranges would be the 200mgTestE 100mg primo one.
pretty grave mistake imo. not a good look.
I would also love to get more infos about this. Hopefully he talks about it at length in some video in the future, or maybe takes some talking time from steve in the next roundtable thingy to explain the design, clarify if any mistakes were made (table contents regarding E2), and if a larger sample is in the works.